Fundraising Fox
Spyglass Pharma
NASDAQ: SGPAliso Viejo, US · Founded 2019 · 77 employees on LinkedIn · 5 known investors
Find your way into Spyglass Pharma
Sign up to see every warm intro you have to Spyglass Pharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Spyglass Pharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
SpyGlass Pharma develops a sustained drug delivery platform for treating chronic ophthalmic diseases such as glaucoma, integrating drugs, procedures, and devices for long-term disease control and vision preservation. It serves the ophthalmic care market, spanning discovery through late-stage clinical development and commercialization.
Founders & leadership
Spyglass Pharma was founded in 2019 by Glenn Sussman and Malik Y. Kahook.
Board
Investors · 5
How we know: the S-1 prospectus · board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: RA Capital's portfolio page · the S-1 prospectus · Not right? Tell us
How we know: Samsara BioCapital's portfolio page · the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$134.8M disclosed across 4 rounds · 2019–2025
▶$75MraisedJun 2025 · 10 investors · Other Health CareRule 506(b)
- Jake MerrillDirector
- Malik KahookExecutive Officer, Director
- Geoff PardoDirector
- Bilal KhanDirector
- Cynthia YeeDirector
- Roger ZhangDirector
- Patrick MooneyExecutive Officer, Director
- Ali BehbahaniDirector
- Zach ScheinerDirector
- Offering amount
- $75M
- Amount sold
- $75M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$40MraisedJul 2023 · 7 investors · Other Health CareRule 506(b)
- Ali BehbahaniDirector
- Patrick MooneyExecutive Officer, Director
- Cynthia YeeDirector
- Malik KahookExecutive Officer, Director
- Roger ZhangDirector
- Zach ScheinerDirector
- Offering amount
- $90M
- Amount sold
- $40M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$13.7MraisedJan 2021 · 4 investors · Other Health CareRule 506(b)
- Kirk NielsenDirector
- Malik KahookExecutive Officer, Director
- Ali BehbahaniDirector
- Tak CheungDirector
- Cynthia YeeDirector
- Glenn SussmanExecutive Officer, Director
- Offering amount
- $37.5M
- Amount sold
- $13.7M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$6MraisedJun 2019 · 2 investors · Other Health CareRule 506(b)
- Malik KahookExecutive Officer, Director
- Ali BehbahaniDirector
- Glenn SussmanExecutive Officer, Director
- Offering amount
- $6M
- Amount sold
- $6M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 2
Companies working in the same space as Spyglass Pharma.
Frequently asked questions
- What does Spyglass Pharma do?
- SpyGlass Pharma develops a sustained drug delivery platform for treating chronic ophthalmic diseases such as glaucoma, integrating drugs, procedures, and devices for long-term disease control and vision preservation. It serves the ophthalmic care market, spanning discovery through late-stage clinical development and commercialization.
- Who founded Spyglass Pharma?
- Spyglass Pharma was founded by Glenn Sussman, Malik Y. Kahook in 2019.
- Who are Spyglass Pharma's investors?
- Spyglass Pharma's investors include New Enterprise Associates (NEA), RA Capital, Samsara BioCapital, Sands Capital Ventures, Vensana Capital.
- How much funding has Spyglass Pharma raised?
- Spyglass Pharma has disclosed $134.8M raised across 4 rounds.
- Where is Spyglass Pharma headquartered?
- Spyglass Pharma is headquartered in Aliso Viejo, US.